首页> 美国卫生研究院文献>other >A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

【2h】

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

机译：Chfiri的I阶段临床试验与Pan-Cyclin依赖性激酶（CDK）抑制剂黄哌啶组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors.

著录项

期刊名称 other
作者
Mark A. Dickson; Manish A. Shah; Dana Rathkopf; Archie Tse; Richard D. Carvajal; Nian Wu; Robert A. Lefkowitz; Mithat Gonen; Lauren M. Cane; Heather J. Dials; Gary K. Schwartz;
展开▼
作者单位

展开▼
年(卷),期 -1(66),6
年度 -1
页码 1113–1121
总页数 16
原文格式 PDF
正文语种
中图分类
关键词
CDKs and CDK inhibitors Phase I trials Gastrointestinal cancers: colorectal Combination chemotherapy Pharmacokinetics and pharmacodynamics Novel antitumor agents;

机译：CDK和CDK抑制剂;I期试验;胃肠道癌：结直肠癌;联合化疗;药代动力学和药效学;新型抗肿瘤药;

相似文献

外文文献
中文文献
专利

1. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. [J] . Dickson MA, Shah MA, Rathkopf D, Cancer chemotherapy and pharmacology. . 2010,第6期

机译：FOLFIRI与泛细胞周期蛋白依赖性激酶（CDK）抑制剂flavopiridol组合的I期临床试验。
2. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol [J] . Mark A. Dickson, Manish A. Shah, Dana Rathkopf, Cancer Chemotherapy and Pharmacology . 2010,第6期

机译：FOLFIRI与泛细胞周期蛋白依赖性激酶（CDK）抑制剂flavopiridol联合进行的I期临床试验
3. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial [J] . LukeJ.J., DAdamoD.R., DicksonM.A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第9期

机译：细胞周期蛋白依赖性激酶抑制剂黄酮哌啶醇可增强阿霉素在晚期肉瘤中的功效：临床前研究和I期剂量递增临床试验的结果
4. Application of a Self-Emulsifying PEG-p-(CL-co-TMC) Micelle System for the Solubilization ofthe Novel Cylin Dependent Kinase (CDK) Inhibitor, JNJ7706621 [C] . M. Brewster, F. Danhier, J-P. Latere DwanIsa, Annual meeting exposition of the Controlled Release Society . 2009

机译：自乳化PEG-p-（CL-co-TMC）胶束系统在新型Cylin依赖性激酶（CDK）抑制剂JNJ7706621增溶中的应用
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose escalation clinical trial [O] . Jason J. Luke, David R. D’Adamo, Mark A. Dickson, -1

机译：细胞周期蛋白依赖性激酶抑制剂Flavopiridol增强了先进的肉瘤中的多柔比蛋白功效：临床前研究和I剂量升级临床试验的结果
7. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol [O] . Mark A. Dickson, Manish A. Shah, Dana Rathkopf, 2010

机译：Chfiri的I阶段临床试验与Pan-Cyclin依赖性激酶（CDK）抑制剂黄哌啶组合

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

摘要

著录项

相似文献

相关主题

期刊订阅